Germinal centre B‐cell‐like (GCB) and activated B‐cell‐like (ABC) are two major molecular subtypes of DLBCL, which are identified by microarray‐based gene expression profiling,1 NanoString nCounter system,2 immunohistochemistry3 and ‘Hans’ classification.4 The chromosomal translocation caused by Myc, Bcl‐2 and/or Bcl‐6 structural reorganization is closely related to the therapeutic effect and prognosis of DLBCL.5 The standard therapeutic process for patients with DLBCL is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP). This evidence concerns the gene MYC and diffuse large B-cell lymphoma.